Clinical Trials Logo

Filter by:
NCT ID: NCT00420927 Completed - Clinical trials for Rheumatoid Arthritis

Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis

OPTIMA
Start date: December 2006
Phase: Phase 4
Study type: Interventional

This study compared the safety and efficacy of combination therapy with adalimumab plus methotrexate (MTX) to that of MTX monotherapy (i.e., placebo plus MTX) in subjects with early rheumatoid arthritis (RA).

NCT ID: NCT00420238 Completed - Clinical trials for Ankylosing Spondylitis

Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis

Start date: January 2007
Phase: Phase 4
Study type: Interventional

Evaluation of the efficacy and safety of etanercept (Enbrel) in patients with active, severe and advanced ankylosing spondylitis.

NCT ID: NCT00417209 Completed - Clinical trials for Pancreatic Neoplasms

Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen

PAPRIKA
Start date: December 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and the safety Larotaxel administered as single agent every 3 weeks to continuous administration of 5-FU every 3 weeks, in patients with advanced pancreatic cancer (non operable in a curative intent, locally recurrent or metastatic) previously treated with gemcitabine based therapy.

NCT ID: NCT00417079 Completed - Neoplasms Clinical Trials

XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer

TROPIC
Start date: January 2007
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, multi-center study comparing the safety and efficacy of XRP6258 plus prednisone to mitoxantrone plus prednisone in the treatment of hormone refractory metastatic prostate cancer previously treated with a Taxotere®-containing regimen. The primary objective is overall survival. Secondary objectives include progression free survival, overall response rate, prostate-specific antigen (PSA) response/progression, pain response/progression, overall safety, and pharmacokinetics. Patients will be treated until disease progression, death, unacceptable toxicity, or for a maximum of 10 cycles. Patients will have long-term follow-up for a maximum of up to 2 years.

NCT ID: NCT00416520 Completed - Clinical trials for Chronic Kidney Disease

A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia

Start date: June 2007
Phase: Phase 3
Study type: Interventional

This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, randomised, parallel group, flexible dose, the third period is a placebo-controlled withdrawal comparing MCI-196 with placebo for 4 weeks.

NCT ID: NCT00415818 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer

Start date: December 2005
Phase: Phase 2/Phase 3
Study type: Interventional

The primary Objective is to assess the efficacy of TG4010 combined to chemotherapy in comparison with chemotherapy alone in patients with advanced non small cell lung cancer.

NCT ID: NCT00415194 Completed - Clinical trials for Head and Neck Neoplasms

A Study for Patients With Head and Neck Cancer

Start date: December 2006
Phase: Phase 3
Study type: Interventional

This study will compare the effects of pemetrexed plus cisplatin versus cisplatin alone in head and neck cancer patients.

NCT ID: NCT00414661 Completed - Clinical trials for Arthritis, Rheumatoid

Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550

Start date: April 2007
Phase: N/A
Study type: Observational

The purpose of this study is to follow the health of subjects who have previously been enrolled in studies of CP-690,550 for treatment of their rheumatoid arthritis. Subjects are only eligible for this study after they have completed all participation in other studies of CP-690,550.

NCT ID: NCT00414609 Completed - Clinical trials for Myocardial Infarction

Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)

Start date: December 2006
Phase: Phase 3
Study type: Interventional

The core and extension studies assessed the safety and efficacy of aliskiren when added to optimized standard therapy in patients that have had a high risk acute myocardial infarction (heart attack).

NCT ID: NCT00413699 Completed - Clinical trials for Arthritis, Rheumatoid

Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Start date: February 5, 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are eligible for this study only after participating in another "qualifying" study of CP-690,550 A sub-study will be conducted within the A3921024 study, this study will evaluate the immune response to pneumococcal and influenza vaccines in patients receiving CP-690,550